Indolent Lymphoma Clinical Trials
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
Q
Recruiting
- Follicular Lymphoma
- +7 more
- Louisville, Kentucky
- +4 more
2022-03-11
Mar 11, 2022T
Recruiting
- CLL
- +9 more
- TG-1801
- Ublituximab
- Fayetteville, Arkansas
- +4 more
2022-03-22
Mar 22, 2022U
Active, not recruiting
- Non Hodgkin Lymphoma
- +8 more
- Miami, Florida
- +2 more
2022-03-08
Mar 8, 2022N
Recruiting
- Lymphoma, Non-Hodgkin
- +9 more
- NKX019
- Denver, Colorado
- +6 more
2022-01-19
Jan 19, 2022B
T
Recruiting
- Indolent Lymphoma
- vegan diet and lifestyle changes
- Tel Aviv, IsraelTel-Aviv Sourasky Medical Center
2021-07-05
Jul 5, 2021S
Recruiting
- B-cell Lymphoma
- +7 more
- Birmingham, Alabama
- +20 more
2020-10-14
Oct 14, 2020U
Completed
- Lymphoma
- +3 more
- rituximab
- +2 more
- Tucson, ArizonaThe University of Arizona Cancer Center
2019-12-16
Dec 16, 2019N
Unknown status
- Indolent Lymphoma
- Ledipasvir and sofosbuvir
- (no location specified)
2017-08-23
Aug 23, 2017G
Terminated
- Indolent Lymphoma
- Therapy with Rituximab, Gemcitabine and Oxaliplatin
- Ludwigshafen, GermanyKlinikum Ludwigshafen
2015-08-17
Aug 17, 2015S
Completed
- Hodgkin Lymphoma
- +2 more
- Omaha, Nebraska
- +4 more
2012-04-19
Apr 19, 2012T
Unknown status
- Soft Tissue Sarcomas
- +9 more
- Tel Aviv, IsraelDepartment of Nuclear Medicine, Tel Aviv Sourasky Medical Center
2008-05-30
May 30, 2008